1. Berglas S, Jutai L, MacKean G, Weeks L. Patients' perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH common drug review. Res Involvement Engagem. 2016;2:21. doi:
10.1186/s40900-016-0036-9
.
2. Best Medicines Coalition. Health technology assessment in Canada: improving the system and ensuring the patient voice is heard. Position paper. 2014.
http://www.bestmedicines.ca/node/168
. Accessed 11 Jul 2016.
3. British Columbia PharmaCare. Conflict of interest guidelines: for the drug benefit review process. British Columbia Ministry of Health Services. 2009.
http://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/dbc-coi-guidelines.pdf
. Accessed 20 Jun 2016.
4. British Columbia PharmaCare. Drug Benefit Council–terms of reference. British Columbia Ministry of Health Services. 2010.
http://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/dbc-termsofref.pdf
. Accessed 20 Jun 2016.
5. CADTH. Canadian Drug Expert Committee: terms of reference. 2011a.
https://www.cadth.ca/media/corporate/corp_committees/CDEC_TOR_e.pdf
. Accessed 20 Jun 2016.